Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

1795.433 - 1818.999 Dr. Andrea Apolo

provide the best overall outcomes for patients safely, of course, but give them the best chance. But we do over-treat patients. And I think that's why one of the reasons these adjuvant trials are so large is because we have to treat a lot of patients in order to see a benefit. And a lot of patients that we're treating, we're over-treating them, right? So not everybody needs it.